European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes.

Breast centre Certification Multidisciplinary Quality control Quality indicators

Journal

Breast care (Basel, Switzerland)
ISSN: 1661-3791
Titre abrégé: Breast Care (Basel)
Pays: Switzerland
ID NLM: 101254060

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 05 08 2019
accepted: 22 09 2019
entrez: 15 1 2020
pubmed: 15 1 2020
medline: 15 1 2020
Statut: ppublish

Résumé

EUSOMA undertook the commitment of defining the requirements for a specialist breast centre, which has become the reference document for the implementation of breast centres. The EUSOMA requirements for a specialist breast centre give clear indications regarding the requisite caseload, dedicated team composition (core and non-core team), organisation, availability of services and equipment throughout the patient pathway, quality control, and application of a multidisciplinary approach. The minimum number of cases is 150 newly diagnosed breast cancer cases per year. Based on the EUSOMA requirements, a voluntary and accredited certification scheme has been developed. In Europe, other voluntary certification schemes are available, such as those developed by the German Cancer Society and German Society for Breast Disease, the National Cancer Peer Review Programme in the UK, and the "label de qualité" established by the Swiss Anticancer League and the Swiss Senology Society. The European Commission Initiative on Breast Cancer (ECIBC) has overseen the development of a European Quality Assurance Scheme. Nearly 20 years after the initial publication of the EUSOMA requirements, ensuring that all breast cancer patients in Europe are treated only in certified breast centres should be considered a high priority and eventually achieved through collaborative efforts.

Sections du résumé

BACKGROUND BACKGROUND
EUSOMA undertook the commitment of defining the requirements for a specialist breast centre, which has become the reference document for the implementation of breast centres.
SUMMARY CONCLUSIONS
The EUSOMA requirements for a specialist breast centre give clear indications regarding the requisite caseload, dedicated team composition (core and non-core team), organisation, availability of services and equipment throughout the patient pathway, quality control, and application of a multidisciplinary approach. The minimum number of cases is 150 newly diagnosed breast cancer cases per year. Based on the EUSOMA requirements, a voluntary and accredited certification scheme has been developed. In Europe, other voluntary certification schemes are available, such as those developed by the German Cancer Society and German Society for Breast Disease, the National Cancer Peer Review Programme in the UK, and the "label de qualité" established by the Swiss Anticancer League and the Swiss Senology Society. The European Commission Initiative on Breast Cancer (ECIBC) has overseen the development of a European Quality Assurance Scheme.
KEY MESSAGES CONCLUSIONS
Nearly 20 years after the initial publication of the EUSOMA requirements, ensuring that all breast cancer patients in Europe are treated only in certified breast centres should be considered a high priority and eventually achieved through collaborative efforts.

Identifiants

pubmed: 31933581
doi: 10.1159/000503603
pii: brc-0014-0359
pmc: PMC6940462
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

359-365

Informations de copyright

Copyright © 2019 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to declare.

Références

Ann Surg. 2018 Feb;267(2):375-381
pubmed: 27893532
Eur J Cancer. 2017 Nov;85:15-22
pubmed: 28881247
Eur J Cancer. 1999 Jan;35(1):14-5
pubmed: 10211082
Eur J Cancer. 2017 Nov;86:59-81
pubmed: 28963914
BMJ. 2012 Apr 26;344:e2718
pubmed: 22539013
Cureus. 2016 Nov 24;8(11):e895
pubmed: 28018765
Eur J Cancer. 2013 Nov;49(17):3579-87
pubmed: 23968730
Eur J Cancer. 2015 Jul;51(10):1221-30
pubmed: 25892645
Eur J Surg Oncol. 2015 Aug;41(8):1005-12
pubmed: 25986853
Eur J Cancer. 2000 Dec;36(18):2288-93
pubmed: 11094301
Am J Public Health. 1998 Mar;88(3):454-7
pubmed: 9518982

Auteurs

Laura Biganzoli (L)

Breast Unit, Nuovo Ospedale di Prato, Prato, Italy.

Lorenza Marotti (L)

EUSOMA, Florence, Italy.

Maria-Joao Cardoso (MJ)

Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Nova Medical School, Lisbon, Portugal.

Luigi Cataliotti (L)

BCCERT and SENONETWORK Italia, Florence, Italy.

Giuseppe Curigliano (G)

Department of Oncology and Haematology, University of Milan, Milan, Italy.
IEO, European Institute of Oncology IRCCS, Milan, Italy.

Jack Cuzick (J)

Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom.

Aaron Goldhirsch (A)

International Breast Cancer Study Group, Bern, Switzerland.
MultiMedica, Milan, Italy.

Marjut Leidenius (M)

Breast Surgery Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.

Robert Mansel (R)

Cardiff University School of Medicine, Cardiff, United Kingdom.

Christos Markopoulos (C)

Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Lynda Wyld (L)

Department of Oncology and Metabolism, University of Sheffield, Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, United Kingdom.

Isabel T Rubio (IT)

Breast Surgical Oncology Unit, Clinica Universidad de Navarra, Madrid, Spain.
Universidad de Navarra, Pamplona, Spain.

Classifications MeSH